Uncomplicated Skin and Skin Structure Infections in Children: Diagnosis and Current Treatment Options in the United States

Abstract

Keywords

skin and skin structure infections Staphylococcus aureus Streptococcus pyogenes treatment impetigo dermatitis antibiotic

Get full access to this article

View all access options for this article.

References

Rosen T.

Update on treating uncomplicated skin and skin structure infections. J Drugs

Dermatol. 2004;4(6 suppl): S9-S14.

Stevens DL , Bisno AL , Chambers HF , et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.

Mangram AJ A brief overview of the 1999 CDC Guideline for the Prevention of Surgical Site Infection. Centers for Disease Control and Prevention. J Chemother. 2001;13:35-39.

Mancini AJ Bacterial skin infections in children: the common and the not so common . Pediatr Ann. 2000;29:26-35.

Oumeish I. , Oumeish OY , Bataineh O. Acute bacterial skin infections in children. Clin Dermatol . 2000;18:667-678.

Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5(suppl 1):35-46.

Larsen F. , Hanifin JM Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22:1-24.

Leung DY Atopic dermatitis: new insights and opportunities for therapeutic intervention . J Allergy Clin Immunol. 2000 ;105:860-876.

Baker BS The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144:1-9.

10.

Stulberg DL , Penrod MA , Blatny RA Common bacterial skin infections. Am Fam Physician . 2002;66:119-124.

11.

Sladden MJ , Johnston GA More common skin infections in children. BMJ. 2005;330:1194-1198.

12.

O'Dell ML Skin and wound infections: an overview. Am Fam Physician. 1998;57:2424-2432.

13.

Hijazy M. Principles of Pediatric Dermatology. http://www.dermatologyinfo.net/english/ebook.htm . Accessed October 6, 2006.

14.

Ladhani S. , Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations . Paediatr Drugs. 2005;7:77-102.

15.

Perera G. , Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005;19:531-545.

16.

Roth RR , James WD Microbiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol. 1989;20: 367-390.

17.

Marples MJ The normal flora of the human skin. Br J Dermatol. 1969;81(suppl 1):2-13.

18.

Steinberg JP , Clark CC , Hackman BO Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis. 1996 ;23:255-259.

19.

Lowy FD Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.

20.

Mainous AG III , Hueston WJ , Everett CJ , et al. Nasal carriage of Staphylococcus aureus and methicillin-resistant S. aureus in the United States, 2001-2002. Ann Fam Med. 2006 ;4:132-137.

21.

Ladhani S. , Joannou CL , Lochrie DP , et al. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev. 1999;12:224-242.

22.

Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4:641-654.

23.

Ong PY , Ohtake T. , Brandt C. , et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151-1160.

24.

Diep BA , Gill SR , Chang RF , et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006;367:731-739.

25.

Cohen PR Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection: a personal perspective of a worldwide epidemic. Expert Rev Dermatol. 2006;1:631-637.

26.

Chen AE , Goldstein M. , Carroll K. , et al. Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care. 2006;22:717-723.

27.

Ochoa TJ , Mohr J. , Wanger A. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis. 2005 ;11:966-968.

28.

Darmstadt GL , Lane AT Impetigo: an overview. Pediatr Dermatol. 1994;11:293-303.

29.

Eron LJ , Lipsky BA , Low DE , et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(suppl 1): 13-17.

30.

Scher RK , Elston DM , Hedrick JA , et al. Treatment options in the management of uncomplicated skin and skin structure infections. Cutis. 2005;75(suppl 1):3-23.

31.

Darmstadt GL Antibiotics in the management of pediatric skin disease. Dermatol Clin. 1998;16:509-525.

32.

Lin RY A perspective on penicillin allergy. Arch Intern Med . 1992;152:930-937.

33.

Pichichero ME A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. 2005;115:1048-1057.

34.

Pichichero ME Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract. 2006;55: 106-112.

35.

Gilbert DN Aspects of the safety profile of oral antibacterial agents. Infect Dis Clin Pract. 1995;4(suppl 2): S103.

36.

Randolph MF , Morris KE Clindamycin-associated colitis in children. A prospective study and a negative report. Clin Pediatr (Phila). 1977;16:722-725.

37.

Elston DM

Optimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J Drugs

Dermatol. 2005;4(suppl 6): S15-S19.

38.

Marcinak JF , Frank AL Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis. 2003;16:265-269.

39.

Thornton Spann C. , Taylor SC , Weinberg JM Topical antimicrobial agents in dermatology . Clin Dermatol. 2003 ;21:70-77.

40.

Thornton Spann C. , Tutrone WD , Weinberg JM , et al. Topical antibacterial agents for wound care: a primer. Dermatol Surg. 2003;29:620-626.

41.

Deshpande LM , Pfaller MA , Fix AM , et al. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. 2002;42:283-290.

42.

Gales AC , Andrade SS , Sader HS , et al. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J Chemother. 2004;16:323-328.

43.

Kaye ET Topical antibacterial agents. Infect Dis Clin North Am. 2000;14:321-339.

44.

Akins RL , Haase KK Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2005;25:1001-1010.

45.

Lewis JS II , Jorgensen JH

Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?

Clin Infect Dis. 2005;40:280-285.

46.

Schweiger ES , Weinberg JM Novel antibacterial agents for skin and skin structure infections. J Am Acad Dermatol. 2004;50:331-340.

47.

Kardas P. , Devine S. , Golembesky A. , et al. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents. 2005;26: 106-113.

48.

Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections . J Antimicrob Chemother. 2002;49:897-903.

49.

Rist T. , Parish LC , Capin LR , et al. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002;27:14-20.

50.

Gardiner P. , Dvorkin L. Promoting medication adherence in children . Am Fam Physician. 2006;74:793-798.

51.

Steele RW , Thomas MP , Begue RE Compliance issues related to the selection of antibiotic suspensions for children . Pediatr Infect Dis J. 2001;20:1-5.

52.

Mupirocin [prescribing information]. http://us.gsk.com/ . Accessed October 6, 2006.

53.

Gales AC , Sader HS , Andrade SS , et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents. 2006;27:300-302.

54.

Hunt E. Pleuromutilin antibiotics. Drugs Future. 2000 ; 25:1163-1168.

55.

Free A. , Roth E. , Dalessandro M. , et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. SkinMed. 2006; 5:224-232.

56.

Parish LC , Jorizzo JL , Breton JJ , et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006;55:1006-1016.